Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schiller, A.
Right arrow Articles by Jung, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schiller, A.
Right arrow Articles by Jung, H. H.
Related Collections
Right arrow Metabolic disease (inherited)
Right arrow Amino acid
Right arrow Dystonia
Right arrow All Genetics
NEUROLOGY 2004;63:1524-1526
© 2004 American Academy of Neurology
Brief Communications

Long-term course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency

A. Schiller, MD, R. A. Wevers, PhD, G. C.H. Steenbergen, PhD, N. Blau, PhD and H. H. Jung, MD

From the Department of Neurology (Drs. Schiller and Jung), University Hospital Zürich; Laboratory of Pediatrics and Neurology (Drs. Wevers and Steenbergen), University Medical Center, Nijmegen, The Netherlands; and Division of Clinical Chemistry and Biochemistry (Dr. Blau), University Children’s Hospital, Zürich, Switzerland.

Address correspondence and reprint requests to Dr. Hans H. Jung, Department of Neurology, University Hospital Zürich, Frauenklinikstrasse 26, 8091 Zürich, Switzerland; e-mail: hans.jung{at}usz.ch

The authors report the long-term course of two siblings with L-dopa responsive dystonia (DRD) associated with a compound heterozygous mutation in the tyrosine hydroxylase (TH) gene. Both siblings manifested with lower-limb onset generalized DRD and had a sustained response to low-dose L-dopa therapy for over 35 years. Although the L-dopa therapy was delayed up to 20 years after disease onset, there were no cognitive or neurologic sequelae of the long-term catecholamine deficit.

Received March 26, 2004. Accepted in final form June 2, 2004.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.